Effect of acute kidney injury requiring extended dialysis on 28 day and 1 year survival of patients undergoing interventional lung assist membrane ventilator treatment by Kielstein, Jan T et al.
RESEARCH ARTICLE Open Access
Effect of acute kidney injury requiring extended
dialysis on 28 day and 1 year survival of patients











2 and Stefan Fischer
3
Abstract
Background: Extracorporeal lung assist devices are increasingly used in the intensive care unit setting to improve
extracorporeal gas exchange mainly in patients with acute respiratory distress syndrome. ARDS is frequently
accompanied by acute kidney injury; however it is so far unknown how the combination of these two conditions
affects long term survival of critically ill patients.
Methods: In a retrospective analysis of a tertiary care hospital we evaluated all patients undergoing interventional
lung assist (iLA) treatment between January 1
st 2005 and December 31
st 2009. Data from all 61 patients (31 F/30
M), median age 40 (28 to 52) years were obtained by chart review. Follow up data up to one year were obtained.
Results: Of the 61 patients undergoing iLA membrane ventilator treatment 21 patients had acute kidney injury
network (AKIN) stage 3 and were treated by extended dialysis (ED). Twenty-eight day survival of all patients was
33%. While patients without ED showed a 28 day survival of 40%, the survival of patients with ED was only 19%.
Patients on ED were not different in respect to age, weight, Horowitz index and underlying disease.
Conclusions: AKI requiring ED therapy in patients undergoing iLA treatment increases mortality in ICU patients.
Patients in whom iLA was placed as a bridge to lung transplantation and that were successfully transplanted
showed the best outcome. Future studies have to clarify whether it is possible to identify patients that truly benefit
from the combination of these two extracorporeal treatment methods.
Background
The most frequent contributing factor to acute kidney
injury (AKI) is sepsis and multi-organ dysfunction syn-
d r o m e( M O D S )[ 1 ] .T h eh i g hm o r t a l i t yr a t eo fp a t i e n t s
with AKI reaches 60% despite considerable improve-
ment of renal replacement therapy (RRT). This fostered
the interest on the impact of AKI on distant organ func-
tion. One interesting interaction is the one between lung
and kidney. AKI induces increased lung vascular perme-
ability, cellular inflammation, and dysregulated salt and
water channels resulting in respiratory failure [2]. Also
in patients with non-severe pneumonia AKI is asso-
ciated with higher immune response and an increased
risk of death [3]. In contrast to several studies investi-
gating the effect of AKI on survival of patients under-
going extracorporeal membrane oxygenation [4,5], there
is only scarce data on the effect of AKI on the survival
of patients undergoing pumpless interventional lung
assist (iLA membrane ventilator; Novalung, Talheim,
Germany) treatment. This technique is increasingly used
by intensivists in patients with life-threatening respira-
tory failure or acute respiratory distress syndrome
(ARDS) suffering from persistent hypercapnia. The 28
day survival of patients undergoing iLA therapy ranges
from 41% in a retrospective analysis [6] to 51% in a
prospective cohort study in patients with ARDS from
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garded patients with AKI on renal replacement therapy
(RRT). Only two studies provide short term survival
data on patients undergoing iLA membrane ventilator
therapy also suffering from AKI. In a retrospective ana-
lysis by Liebold et al. 39% of the iLA patients required
intermittent haemodialysis [8]. In a study by Floerchin-
ger et al. 42% of the patients were treated by continuous
veno-venous hemofiltration (CVVH) [9]. So far it is
unknown, what impact extended dialysis (ED), an
increasingly used RRT method in the ICU [10,11], has
on long term survival of patients undergoing iLA treat-
ment. Moreover, it is not known whether the improve-
ment in respiratory acidosis has any impact on renal
function in these patients. Hence, the aim of our study
was to investigate the effect of AKI on long term
mortality of patients treated by iLA. Furthermore the
potential impact of iLA treatment on renal function was
investigated in this single centre retrospective study.
Methods
This retrospective cohort study included all adult
patients that underwent iLA treatment from Januar 1st
2005 to December 31st 2009 at a tertiary care university
hospital. The Institutional Review Board of the Medical
School Hannover waived the need for approval and
informed consent for this analysis. A total of 61 patients
were identified in the central documentation system of
the hospital. From all of those patients charts as well as
laboratory data were reviewed. RRT dependence was
defined as AKIN stage 3. All patients requiring RRT
in addition to iLA treatment received ED using the
GENIUS system. Details of the system are summarized
elsewhere [11].
Estimated glomerular filtration rate (eGFR) was calcu-
lated using the CKD-EPI formula [12].
Statistical analysis
We used GraphPad Prism 5 for statistical analysis.
ANOVA was used to compare patients requiring
extended dialysis to patients undergoing iLA therapy
only. Kaplan-Meier plots were analyzed for significance
using the Kruskal-Wallis test. The significance level was
set at p < 0.05.
Results
We identified 61 patients undergoing iLA treatment
within our observation period of five years. Patient char-
acteristics are presented in Table 1. The underlying dis-
eases are summarized in Table 2. More than one third
(n = 21, 34%) of all patients required ED. Exactly one
third of these patients had already been RRT dependent
before (n = 7; 33%) iLA insertion. Half of the patients
became RRT dependent on the day of iLA insertion
(n = 10; 48%). Within two days after iLA placement
another five patients (24%) became RRT dependent.
Hence, within two days of iLA insertion 71% (n = 15) of
patients ever to become RRT dependent were on ED
(Figure 1). This corresponds to roughly 25% of all
patients undergoing iLA treatment. Patients undergoing
ED treatment were not different in respect to gender,
age, weight, iLA support duration, use of nephrotoxic
antiobiotics, PaO2,p a C O 2,H o r o w i t zi n d e x ,M A P ,P max
and PEEP at start of iLA support (Table 1) and underly-
ing disease to patients not requiring RRT. Also time
from ICU admission to iLA insertion was not different
in the two groups. However, patients undergoing ED
had a significant lower pH, a higher SOFA and
APACHE II score as well as a significant higher iLA
flow 2 h after implantation than patients not requiring
RRT (p < 0.05) (Table 1). The 28 day survival of the
whole cohort was 23%. There was a clear difference in
survival between patients requiring ED and those not
requiring RRT. While patients undergoing ED exhib-
ited a 19% 28 day survival, the survival rate at day 28
in patients without need for dialysis was 40% (p =
0.001) (Figure 2). This difference became even more
marked after one year. While patients undergoing ED
had a 5% one year survival, patients without the need
for RRT had a 25% one year survival (p < 0.001).
Patients in whom iLA was placed as a bridge to lung
transplantation and that were successfully transplanted
showed a markedly higher 28 day survival rate of 78%,
while all of the patients listed for lung transplantation
without subsequently receiving a graft died before day
25 (Figure 3). In contrast to the whole cohort, the
necessity of RRT had no effect on survival in the trans-
plant candidates.
Not surprisingly, the median eGFR of patients with no
current or future need of ED on admission to the ICU
was 124 (100 to 140) [ml/min/1.73 m
2]. Patients which
became RRT dependent had a significant lower eGFR
(66 (33 to 138) [ml/min/1.73 m
2]). Despite the improve-
ment in pH and pCO2 the insertion of iLA had no effect
on renal function in patients that did not become RRT
dependent (Table 1).
Discussion
The pertinent findings of our study were that 1) the
combination of iLA treatment and ED is associated with
an increased short and long term mortality 2) most of
t h ep a t i e n t sw i t ht h i sc o m b i nation either were dialysis
dependent before the start of iLA treatment or within
48 hours after start of iLA therapy 3) the bridging to
successful lung transplantation was associated with the
best 28 day survival 4) decreased eGFR at the time on
the day of iLA institution was predictive of future dialy-
sis dependence.
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This report is the first evaluation of the influence of ED
on the survival of patients undergoing iLA treatment.
Two previous studies on iLA treatment did not address
this issue of AKI and renal replacement therapy at all
[6,7]. The rate of patients requiring renal replacement
therapy in our cohort (34%) is comparable with two
Table 1 Patient characteristics before iLA insertion (unless otherwise stated)
all iLA and ED iLA - no ED p
patients 61 21 40
male/female 30 | 31 9 | 12 21 | 19
age (years) 40 (28 to 52) 36 (28 to 52) 41 (28 to 49) 0.942
iLA treatment (days) 6 (3 to 11) 5 (2 to 9) 7 (5 to 13) 0.191
iLA-flow after 2 h (l/min) 1.1 (1.0 to 1.4) 1.4 (1.3 to 1.6) 1.1 (1.0 to 1.1) 0.009
days on ICU until iLA 7 (3 to 15) 8 (5 to 16) 7 (3 to 12) 0.880
paO2 (mmHg) 82 (70 to 98) 77 (70 to 96) 82 (70 to 100) 0.97
after 24 h iLA 68 (65 to 84) 71 (62 to 90) 78 (68 to 83) 0.900
paCO2 (mmHg) 100 (81 to 115) 98 (81 to 114) 100 (79 to 115) 0.880
after 24 h iLA 52 (43 to 61) 44 (53 to 59) 56 (45 to 61) 0.840
pH 7.15 (7.08 to 7.26) 7.10 (7.04 to 7.15) 7.23 (7.13 to 7.27) 0.007
after 24 h iLA 7.38 (7.31 to 7.46) 7.34 (7.26 to 7.35) 7.41 (7.33 to 7.46) 0.013
Horowitz index (PaO2/FiO2) 96 (75 to 137) 98 (77 to 114) 94 (67 to 144) 0.280
MAP (mmHg) 80 (75 to 86) 80 (70 to 85) 80 (78 to 87) 0.249
Pmax (cmH2O) 38 (34 to 41) 38 (35 to 40) 39 (32 to 42) 0.747
PEEP (cmH2O) 8 (5 to 10) 9 (5 to 13) 8 (5 to 10) 0.370
Creatinine* (μmol/l) 53 (40 to 91) 93 (49 to 174) 50 (37 to 73) 0.005
after 24 h iLA 52 (34 to 78)
eGFR* (ml/min/1,73 m
2) 120 (79 to 138) 66 (33 to 138) 124 (100 to 140) 0.003
SOFA-Score 11 (10 to 12) 14 (11 to 17) 11 (10 to 11) < 0.0001
APACHE II - Score 32 (28 to 34) 32 (31 to 38) 31 (28 to 33) 0.023
Vancomycin use day 1-3 of iLA 32% 40% 29%
Aminoglycoside use day 1-3 of iLA 26% 13% 32%
28 day survival 33% 19% 40%
one year survival 18% 5% 25%
Data presented as median (interquartile ranges). *Creatinine and eGFR only from patients without ED dependence before iLA insertion.
Table 2 Underlying disease and survival at 28 days and
one year
underlying disease n 28 day survival one year survival
cystic fibrosis 15 27% 27%
pneumonia 10 40% 20%
status post lung Tx 8 25% 13%
pulmonary fibrosis 7 43% 0%
COPD 7 29% 0%
lung cancer 2 50% 0%
pulmonary hypertension 2 100% 50%
leukemia 2 50% 50%
polytrauma 2 50% 50%
others 6 17% 17%
Figure 1 Depicts the percentage of RRT (renal replacement
therapy) dependent patients in relation to the iLA-
implantation. Refers to RRT dependent patients (n = 21) only.
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requiring renal replacement therapy was 39 and 42%
[8,9]. These studies also investigated the influence of
either intermittent hemodialysis [8] or CVVH [9] on
survival. In the retrospective analysis by Liebold and co-
workers 39% of all patients required intermittent hemo-
dialysis [8]. These authors reported also a low survival
rate of 15% (4 out of 27 patients), in patients requiring
both dialysis and iLA, while 21 of 43 (49%) of those
patients not requiring dialysis survived. In the study by
Floerchinger et al. 42% of the patients required CVVH.
The survival rate of those patients was 19%. The fact
that outcome is worse in a given acutely ill patient
population, if AKI necessitating RRT develops, is of
course not exceptional and has been depicted in many
populations (for review see [13]). Indeed, patients that
needed both iLA and ED were sicker as reflected by disease
severety scores, a difference however mainly caused by the
deteriorating renal function. Interestingly, the use of
nephrotoxic antibiotics in both groups was not different.
Still, the exceptionally high mortality of 81% in patients
suffering from (temporary) two organ failure in our analysis
is remarkable as the average hospital mortality in ICU
patients requiring RRT was 60% in a large multinational
study [1]. The effect of RRT on survival was not detectable
in patients who survived until lung transplantation, indicat-
ing that prognosis of critically ill patients improves if one
organ system can be substantially improved.
Effect of iLA on renal function
Preclinical data suggested that respiratory acidosis
induces a drop in GFR, effective renal plasma flow and
urine output [14]. Accordingly we assumed that ameli-
oration of respiratory acidosis would improve renal
function. However, for those patients not undergoing
RRT serum creatinine did not significantly change over
the period of iLA support.
We wish to point out limitations of our study. Firstly
the retrospective design and the single centre setting are
important limitations, yet we included patients from dif-
ferent departments, i.e. surgical and medicine, into the
analysis. Also the number of patients is limited, however
our 21 patients with iLA and ED treatment significantly
add to the 27 and 67 patients treated by iLA and RRT
published previously [8,9]. Moreover our study provides
a one year follow up of the patients, which has so far
not been reported by any other group investigating the
effect of the combination of RRT and iLA treatment.
Another important limitation is the fact that we
included a heterogeneous set of patients in which 36%
were either status post transplantation or underwent
lung transplantation after iLA treatment. Last but not
least we did exclude patients on extracorporeal mem-
brane oxygenation
Conclusion
The combination of iLA treatment with acute kidney
injury requiring renal replacement therapy dramatically
increases mortality. Most of the patients that become
dialysis dependent do so within 48 hours of iLA inser-
tion. These patients have already a decreased eGFR at
the time of ICU admission. The best outcome in our
cohort could be obtained in patients that were success-
fully bridged to transplantation.
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Figure 2 Kaplan Meier survival curve of patients undergoing
iLA treatment only (n = 40) or the combination of iLA
treatment and ED (extended dialysis) (n = 21).
Figure 3 Kaplan-Meier survival curves of patients successfully
bridged to lung transplantation (n = 18) or patients with HU
(high urgency) status not being transplanted (n = 17). Survival
in both groups was not affected by the need for ED (extended
dialysis).
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